Jim Cramer Recently Looked At These 16 Stocks
“If you want clean energy, nuclear is the best solution long term. But man, it takes a very, very, very long time to build these things, even the small forms… are still novel and nuclear.
Dynavax Technologies Corp (DVAX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 15,726,349 | $156,162,646 | -12% | 4.36% |
| 2. | Millennium Management Israel Englander | 4,528,415 | $44,967,161 | +181% | 0.02% |
| 3. | Renaissance Technologies Jim Simons | 3,138,547 | $31,165,772 | +9% | 0.04% |
| 4. | Kynam Capital Derrick Tang | 2,145,319 | $21,303,018 | 1.59% | |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 2,036,003 | $20,217,511 | +13% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.82 | 3,800 | $41,116.00 | 35,004 | 2025-08-22 | Filing | |
| $5.00 | 1,000,000 | $5,000,000.00 | 8,525,000 | 2020-05-27 | Filing | |
| $3.00 | 16,666 | $49,998.00 | 30,468 | 2019-08-12 | Filing | |
| $3.00 | 16,667 | $50,001.00 | 16,667 | 2019-08-12 | Filing | |
| $3.00 | 16,667 | $50,001.00 | 118,484 | 2019-08-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.64 | 114,000 | $1,782,960.00 | 63,344 | 2026-01-15 | Filing | |
| $15.49 | 30,000 | $464,700.00 | 111,451 | 2025-12-24 | Filing | |
| $10.59 | 970,143 | $10,273,814.37 | 15,726,349 | 2025-08-22 | Filing | |
| $11.03 | 1,094,994 | $12,077,783.82 | 16,696,492 | 2025-08-21 | Filing | |
| $14.00 | 10,000 | $140,000.00 | 8,078 | 2025-03-24 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,027,448 | $123,462,151 | 0% | |
| 2. | 3,469,580 | $53,362,140 | 1.32% | |
| 3. | 801,336 | $12,328,554 | 0.01% | |
| 4. | 260,511 | $4,006,659 | 0% | |
| 5. | 233,009 | $3,583,678 | 0.03% |
News See All
Dynavax (DVAX) Rockets 38% on Sanofi $2-Billion Merger
In a statement, Dynavax Technologies Corp.
Dynavax Technologies Corporation (NASDAQ:DVAX) Q3 2025 Earnings Call Transcript
Dynavax Technologies Corporation (NASDAQ:DVAX) Q3 2025 Earnings Call Transcript November 5, 2025Dynavax Technologies Corporation beats earnings expectations.
Dynavax Technologies Corporation (DVAX) Reports Record $92M HEPLISAV-B Revenue, Raises 2025 Outlook
Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company specializing in innovative vaccines, is gaining momentum with strong financial results and pipeline progress...
11 Best Pharma Stocks to Invest in for the Long Term
According to a recent White House announcement, President Trump wrote letters to 17 major pharmaceutical companies outlining the actions they could take to bring the prices of prescription pharmaceuticals...
Dynavax Technologies Corporation (NASDAQ:DVAX) Q2 2025 Earnings Call Transcript
Dynavax Technologies Corporation (NASDAQ:DVAX) Q2 2025 Earnings Call Transcript August 7, 2025Dynavax Technologies Corporation beats earnings expectations.
Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31
Dynavax Technologies Corporation (NASDAQ:DVAX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.
13 Best Pharma Stocks to Buy According to Wall Street Analysts
On June 24, Jared Holz, Mizuho's healthcare strategist, appeared on CNBC's 'Fast Money' to talk about competition in the obesity drug space.
Dynavax Technologies Corporation (NASDAQ:DVAX) Q1 2025 Earnings Call Transcript
Dynavax Technologies Corporation (NASDAQ:DVAX) Q1 2025 Earnings Call Transcript May 6, 2025Dynavax Technologies Corporation misses on earnings expectations.
12 Best Small Cap Pharma Stocks to Buy Now
Emily Field, Head of European Pharma Research at Barclays, spoke on CNBC on February 20 about the performance of obesity medications, the effects of US tariffs, and the dynamics of the pharmaceutical ...
Hedge Fund Resource Center Billionaire Hedge Funds
